Valicenti Advisory Services Inc. Has $4.94 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Valicenti Advisory Services Inc. decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,385 shares of the company’s stock after selling 418 shares during the period. AstraZeneca makes up 1.2% of Valicenti Advisory Services Inc.’s holdings, making the stock its 26th biggest holding. Valicenti Advisory Services Inc.’s holdings in AstraZeneca were worth $4,939,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. McClarren Financial Advisors Inc. grew its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Albion Financial Group UT increased its position in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after buying an additional 248 shares in the last quarter. Groupama Asset Managment raised its stake in AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC bought a new position in AstraZeneca in the third quarter worth approximately $45,000. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $69.99 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market cap of $217.03 billion, a PE ratio of 33.53, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. The stock’s fifty day simple moving average is $66.69 and its two-hundred day simple moving average is $74.02. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue was up 18.0% on a year-over-year basis. During the same period last year, the firm earned $0.87 earnings per share. As a group, analysts forecast that AstraZeneca PLC will post 4.12 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.